AngioDynamics delivered a solid QQ2 2026 performance led by a resilient Med Tech franchise. Revenue rose 8.8% year over year to $79.4 million, with Med Tech up 13% and Med Device up 5.6%. The company exhibited meaningful gross-margin expansion to 56.4% (+170 bp YoY), driven by a favorable mix shift toward higher-margin Med Tech products, price realization, and accelerated manufacturing-transfer benefits (Costa Rica transition). Management reaffirmed and raised guidance for the full year, signaling confidence in sustaining growth while funding clinical data investments that are expected to weigh on EBITDA in the back half. Adjusted EBITDA totaled $5.9 million in the quarter (France distribution transaction contributed approximately $1.4 million of adjusted EBITDA), and the company remains cash-flow positive, generating $4.7 million of operating cash flow and ending the quarter with $41.6 million in cash and equivalents. Management emphasized breadth of execution across the portfolio, notably continued Auryon strength (18th consecutive quarter of double-digit YoY growth), momentum in mechanical thrombectomy (AlphaVac leading growth, AngioVac stabilizing after a strong prior-year quarter), and NanoKnife adoption following CPT-code activation, plus regulatory and clinical pipeline catalysts that could sustain growth longer-term. The leadership transition announced by the CEO was noted as well, with a board-driven process expected in fiscal 2027.